The J.P. Morgan Healthcare Conference started off with a flurry of deals that reinvigorated excitement across the biopharma industry. Johnson & Johnson moved to acquire Intra-Cellular Therapies for $14.6 billion, breaking a dealmaking barrier that kept Big Pharma’s 2024 biotech buyouts to under $5 billion.
Deep Dive: JPM M&A Rush Just the Start, as Biopharma Insider Predicts Mega-Deals to Come Read More »
The CMS released highly anticipated MA enrollment data on Tuesday that showed UnitedHealth further tightening its grip on the privatized Medicare market.
Medicare Advantage growth slows as UnitedHealthcare nabs members, Humana sheds lives Read More »
Los implantes dentales son una de las soluciones más efectivas y duraderas para reemplazar piezas dentales ausentes. Sin embargo, existen muchas creencias erróneas sobre este tratamiento odontológico. En este artículo, aclaramos los principales mitos y verdades …
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using these therapies to treat conditions like heart disease risk that have existing cheap standards of care.
As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access Read More »
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma Read More »
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug Read More »
Our CEO accidentally started a book club. Now we’re all dreaming of mega pharma mergers.
The BioSpace Book Club Investigates the Biggest Deals of All Time Read More »
The pathologists group wants the HHS to terminate the regulation in light of an executive order from President Trump that calls for federal agencies to “alleviate unnecessary regulatory burdens.”
CAP urges HHS to revoke lab developed test rule, citing Trump order Read More »
Staar’s job cuts come “amid ongoing macroeconomic and geopolitical challenges that have pressured the business,” a spokesperson said. Demand in China, the company’s largest market, has slowed.
Staar Surgical to lay off 115 people in California Read More »
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More Read More »
